Home / Business News

Business News

Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates

VIENNA–(BUSINESS WIRE)–Themis Bioscience announced today a research collaboration and exclusive license agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) for the discovery and development of undisclosed vaccine candidates using Themis’ measles virus vector-based platform. “Given the versatility of our immune-modulation platform and our proven ability to rapidly …

Read More »

Sobi Sells FDA Priority Review Voucher to AstraZeneca for $95 Million

STOCKHOLM, Aug. 22, 2019 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of USD 95 M. A PRV entitles the holder to FDA priority …

Read More »

Tonix and Massachusetts General Hospital Partner to Develop TNX-1500 for Treatment and Prevention of Organ Transplant Rejection

NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a research collaboration agreement with Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School, to develop TNX-1500, a humanized monoclonal antibody …

Read More »

Cara Therapeutics Enters into License Agreement with Enteris BioPharma for Peptelligence Oral Formulation Technology

BOONTON, N.J., Aug. 21, 2019 /PRNewswire/ — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, today announced its entry into a definitive licensing agreement with Cara Therapeutics (Nasdaq: CARA) for Enteris’ Peptelligence® technology in the ongoing development of an oral …

Read More »

Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix

MIRAMAR, Fla., Aug. 19, 2019 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) is pleased to announce that Generex has acquired an additional 38% of Olaregen Therapeutix for a total Generex ownership of approximately 99% after the share exchange at $2.50 a share for GNBT stock, in a cashless …

Read More »

Agilent Technologies Introduces Revolutionary Real-Time Cell Analyzer

Agilent Technologies Inc. (NYSE: A) today introduced a multimode real-time cell analyzer (RTCA)—the first of its kind—combining the best of non-invasive biosensor measurement with live cell imaging.  “The xCELLigence RTCA eSight will revolutionize cell analysis in life science research,” said Todd Christian, Agilent vice president, and general manager of the company’s Cell …

Read More »

Ultragenyx and GeneTx Partner to Advance Investigational GTX-102 for the Treatment of Angelman Syndrome

NOVATO, Calif. and DOWNERS GROVE, Ill., Aug. 14, 2019 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, and GeneTx Biotherapeutics LLC, today announced a partnership to develop GeneTx’s GTX-102, an antisense oligonucleotide (ASO) for …

Read More »

CureVac and Yale University Partner for Discovery Research in mRNA-Based Lung Therapy Candidates

TÜBINGEN, Germany and BOSTON, Aug. 13, 2019 (GLOBE NEWSWIRE) — CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today it has entered into a Collaborative Research Agreement (“CRA”) with Yale University for discovery research into mRNA-based pulmonary therapeutic candidates.  The exclusive CRA covers the …

Read More »

Leo Pharma Acquires Expanded Global Rights to Develop and Market Brodalumab for Moderate-to-Severe Psoriasis

BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma A/S, a global leader in medical dermatology, today announced it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum® in the European Union) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licencing agreement with Bausch Health Ireland Limited. The …

Read More »

Jazz Pharmaceuticals to Acquire Cavion for up to $312.5 Million

DUBLIN, Aug. 12, 2019 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the acquisition of Cavion, Inc. through a merger with a Jazz subsidiary.  Under the terms of the agreement, the former Cavion shareholders receive an upfront payment of $52.5 million and have the potential to receive additional payments …

Read More »